Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$3.0 - $10.45 $338,775 - $1.18 Million
-112,925 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$7.57 - $21.72 $558,083 - $1.6 Million
73,723 Added 188.06%
112,925 $82,000
Q4 2021

Feb 11, 2022

BUY
$19.68 - $28.68 $145,789 - $212,461
7,408 Added 23.3%
39,202 $66,000
Q3 2021

Nov 04, 2021

BUY
$26.16 - $40.68 $831,731 - $1.29 Million
31,794 New
31,794 $69,000

Others Institutions Holding AVTX

# of Institutions
1
Shares Held
34.6K
Call Options Held
0
Put Options Held
0

About Avalo Therapeutics, Inc.


  • Ticker AVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,414,100
  • Market Cap $118M
  • Description
  • Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...
More about AVTX
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.